1
|
Li J, Li P, Li J, Yang H, Liu G, Shen P, Jiang G. Effects of the Methylation Levels for the Breast Cancer Associated Genes BCSG1 and BRCA1 on Cellular Proliferation and Migration. Genet Test Mol Biomarkers 2022; 26:422-429. [PMID: 36166741 DOI: 10.1089/gtmb.2021.0304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Objective: The aim of this study was to determine whether the methylation patterns of the breast cancer-specific gene 1 (BCSG1) and the breast cancer susceptibility gene 1 (BRCA1) can be used as biomarkers for predicting the occurrence and development of breast cancer. Methods: Methylation-specific polymerase chain reaction (PCR) was used to detect the methylation status of the BCSG1 and BRCA1 genes in ductal infiltrating carcinomas of the breast; carcinoma in situ of the breast; fibroadenoma of the breast and adjacent normal tissues. Quantitative real-time PCR and immunohistochemistry were used to detect the expression levels of BCSG1 and BRCA1. The BCSG1 and BRCA1 genes were knocked down by siRNA to study their effect of BCSG1 and BRCA1 on the behaviour of breast cancer cell lines. Results: The BCSG1 gene was hypomethylated in breast cancer tissues, and its mRNA as well as its protein levels showed elevated expression compared to normal adjacent tissues. In contrast, the BRCA1 gene was hypermethylated in breast cancer tissues and showed correspondingly decreased mRNA and protein expression levels. In vitro experiments demonstrated that BCSG1 could promote the proliferation and migration of breast cancer cells. After inhibiting the methylation, the expression of both the BCSG1 and BRCA1 genes were increased. Conclusion: Abnormal methylation patterns of the BCSG1 and BRCA1 genes are associated with the development of breast cancer. Thus, methylatedion analyses of these genes have biomarker potential for breast cancer prognoses.
Collapse
Affiliation(s)
- Junkuo Li
- Department of Pathology, Anyang Tumor Hospital, Anyang, China
| | - Pan Li
- Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Jia Li
- Department of Pathology, Anyang Tumor Hospital, Anyang, China
| | - Haijun Yang
- Department of Pathology, Anyang Tumor Hospital, Anyang, China
| | - Guohua Liu
- Department of Pathology, Anyang Tumor Hospital, Anyang, China
| | - Peihong Shen
- Department of Pathology, Zhengzhou University Affiliated Tumor Hospital, Zhengzhou, China
| | - Guozhong Jiang
- Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| |
Collapse
|
2
|
Upregulation of Synuclein-γ and Snai1 Contributes to Poor Clinical Prognosis in Oral Squamous Cell Carcinoma Patients. BIOMED RESEARCH INTERNATIONAL 2022; 2022:6534626. [PMID: 35434126 PMCID: PMC9010211 DOI: 10.1155/2022/6534626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 02/21/2022] [Accepted: 03/10/2022] [Indexed: 12/09/2022]
Abstract
Synuclein-γ (SNCG) and Snai1 play an important role in the occurrence and development of different types of malignant tumors. However, the association between SNCG and Snai1 and the effect of their combination on oral squamous cell carcinoma (OSCC) are unknown. The purpose of this study was to assess the expression of SNCG and Snai1 in OSCC tissues and their role in the genesis, development, diagnosis, and prognosis of OSCC. In this study, we first analyzed the Gene Expression Omnibus (GEO) database to determine the expression of SNCG and Snai1 in OSCC. And we also evaluated the correlation between the expression of SNCG and Snai1 and clinical pathological parameters in OSCC from The Cancer Genome Atlas (TCGA) database. Then, the expression of SNCG and Snai1 in OSCC and its adjacent tissues in our experimental cohort were detected by qRT-PCR, Western blot, and immunohistochemistry, and the relationship between their expression and clinical pathological parameters were analyzed. At the same time, the correlation between the expression of SNCG and Snai1 was analyzed from the TCGA, GEO database, and our experimental cohort. Next, the ROC curves were constructed to explore the diagnostic value of SNCG and Snai1 in OSCC. Finally, the survival curves were drawn, and the univariate and multivariate Cox regression analyses were performed to determine the prognostic value of SNCG and Snai1 in OSCC. The study found that SNCG and Snai1 were highly expressed in OSCC tissues. The expression of SNCG was related to the differentiation of OSCC, while that of Snai1 was related to the T stage, lymph node metastasis, clinical stage, and differentiation. Besides, the expression of SNCG in OSCC was positively correlated with that of Snai1. In addition, we also found that SNCG and Snai1 could well distinguish OSCC patients from normal people; especially, the combined diagnosis of SNCG and Snai1 had a better effect, with a specificity up to 96.67%. Moreover, SNCG-negative/Snai1-negative OSCC patients had the best prognosis. Multivariate analysis displayed that SNCG-positive expression was an independent risk factor for prognosis in OSCC patients. The results of this study strongly suggested that SNCG and Snai1 might have a cooperative effect in the occurrence and development of OSCC. They may become new markers for the diagnosis and prognosis of OSCC.
Collapse
|
3
|
Zhang L, Yang X, Tian Y, Yu Q, Zhou D, Wu Z, Zhao X. Noninvasive Detection of Esophageal Cancer by the Combination of mSEPT9 and SNCG. Genet Test Mol Biomarkers 2022; 26:8-16. [PMID: 35089073 DOI: 10.1089/gtmb.2021.0089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background: Esophageal cancer (EC) is the second most common malignant tumor of the digestive system. There is currently no effective noninvasive method for early detection of EC. Methods: We performed a prospective cohort study involving 188 EC patients, 125 patients with benign esophageal diseases, and 270 normal subjects to examine the performance of methylated SEPT9 (mSEPT9) and synuclein gamma (SNCG) individually and in combination. Results: The sensitivity of mSEPT9 and SNCG for EC was 43.1% (AUC = 0.69) at 95.6% specificity and 41.8% (AUC = 0.79) at 92.6% specificity, respectively. The combined detection increased the sensitivity to 71.8% at 90.3% specificity. The combined detection sensitivity for stage I-IV EC was 66.7%, 58.3%, 75.0%, and 88.2%, respectively. No significant difference in combined sensitivity was found among patients with EC of the upper, middle, and lower esophagus, and no significant difference in sensitivity was found between adenocarcinoma and squamous carcinoma. The sensitivity of highly differentiated EC was found to be higher than that of moderately and poorly differentiated EC with SNCG and combined detection. The sensitivity of SNCG in female patients was significantly higher than that in male patients, leading to the same trend in combined detection. Patients aged 40-49 years showed higher combined sensitivity. The sensitivity of SNCG was much higher than that of existing protein markers for digestive cancers. Furthermore, mSEPT9 was capable of predicting the long-term survival of EC patients with a hazard ratio of 2.65. Conclusion: The combined sensitivity of mSEPT7 and SNGG provided significant improvement over any single biomarker for the early detection of EC. mSEPT7 may be useful as a prognostic marker for long-term survival.
Collapse
Affiliation(s)
- Lei Zhang
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. China
| | - Xueying Yang
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. China
| | - Ye Tian
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. China
| | - Qian Yu
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. China
| | - Di Zhou
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. China
| | - Zhuo Wu
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. China
| | - Xitong Zhao
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. China
| |
Collapse
|
4
|
Liu C, Qu L, Zhao C, Shou C. Extracellular gamma-synuclein promotes tumor cell motility by activating β1 integrin-focal adhesion kinase signaling pathway and increasing matrix metalloproteinase-24, -2 protein secretion. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2018; 37:117. [PMID: 29903032 PMCID: PMC6003176 DOI: 10.1186/s13046-018-0783-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 05/14/2018] [Indexed: 12/12/2022]
Abstract
Background Increasing evidence reveals a significant correlation between gamma-synuclein (SNCG) level and tumor invasion and metastasis in various human cancers. Our previous investigation showed that SNCG could secrete into extracellular environment and promoted tumor cell motility, but the mechanism is unknown. Methods The membrane binding ability of SNCG was characterized by immunohistochemical staining, immunofluorescence staining and fractionation of colorectal cancer (CRC) cell membrane. Association between SNCG and β1 integrin was validated by coimmunoprecipitation and far Western blot. After inhibition of β1 integrin and focal adhesion kinase (FAK), effect of SNCG on cell motility was measured by transwell chamber assays and changes of protein levels were detected by Western blot. Association between SNCG and activated β1 integrin levels in human CRC tissues was determined by Spearman’s rank correlation analysis. Secreted proteins in conditioned medium (CM) were screened by antibody array. Results Extracellular SNCG bound β1 integrin on CRC cell membrane and increased levels of activated β1 integrin and FAK. Correspondingly, SNCG-enhanced cell motility was counteracted by knockdown or inhibition of β1 integrin or FAK. Further study revealed that high SNCG level indicated poor outcome and SNCG levels positively correlated with those of activated β1 integrin and phospho-FAK (Tyr397) in human CRC tissues. Additionally, extracellular SNCG promoted secretion of fibronectin (FN), vitronectin (VN), matrix metalloproteinase (MMP)-2, and MMP-24 from HCT116 cells. Protease activity of MMP-2 in the CM of HCT116 cells was increased by treatment with SNCG, which was abolished by inhibiting β1 integrin. Conclusion Our results highlight the potential role of SNCG in remodeling extracellular microenvironment and inducing β1 integrin-FAK signal pathway of CRC cells. Electronic supplementary material The online version of this article (10.1186/s13046-018-0783-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Caiyun Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China. .,Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China.
| | - Like Qu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China.,Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Chuanke Zhao
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China.,Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Chengchao Shou
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China. .,Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China.
| |
Collapse
|
5
|
He X, Zheng Y, Zhang Y, Gan Y, Zhou Y, Liang H, Wu D, Ge W, Deng J, Xu X. Long non-coding RNA AK058003, as a precursor of miR-15a, interacts with HuR to inhibit the expression of γ-synuclein in hepatocellular carcinoma cells. Oncotarget 2018; 8:9451-9465. [PMID: 28035067 PMCID: PMC5354744 DOI: 10.18632/oncotarget.14276] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Accepted: 12/15/2016] [Indexed: 01/20/2023] Open
Abstract
Long non-coding RNAs (lncRNAs) have been identified as critical players in multiple cancers and lncRNAs are tightly linked to cancer progression. However, only little amount of lncRNAs have been identified to participate in the molecular mechanisms of the progression of hepatocellular carcinoma. In this study, we found that lncRNA-AK058003 is down-regulated in hepatocellular carcinoma tissues and it is associated with the relapse and metastasis of the cancer. Furthermore, lncRNA-AK058003 acts as a tumor suppressor, suppressing hepatocellular carcinoma cell proliferation and metastasis in vitro and in vivo. lncRNA-AK058003 can reduce mRNA stabilizing protein HuR, which results in the inhibition of the expression of γ-synuclein. In addition, a bioinformatics study indicated that γ-synuclein is a target of miR-15a. To verify whether lncRNA-AK058003 plays a role in miR-15a-mediated inhibition of γ-synuclein, we demonstrated that lncRNA-AK058003 is very likely to be a precursor of miR-15a. Collectively, lncRNA-AK058003 can reduce the expression of mRNA stabilizing protein HuR and act as a precursor of miR-15a to suppress γ-synuclein-mediated cell proliferation and the metastasis of hepatocellular carcinoma.
Collapse
Affiliation(s)
- Xiaoqin He
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
| | - Yongfa Zheng
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
| | - Yuefeng Zhang
- Department of Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Yuanyuan Gan
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
| | - Yujie Zhou
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
| | - Huilin Liang
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
| | - Dongcheng Wu
- Department of Biochemistry and Molecular Chemistry, School of Basic Medicial Sciences, Wuhan University, Wuhan, China
| | - Wei Ge
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
| | - Junjian Deng
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
| | - Ximing Xu
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
| |
Collapse
|
6
|
Liu C, Shi B, Hao C, Wang Q, Lv Q, Xing N, Shou J, Qu L, Gao Y, Qin C, Zhao J, Shou C. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer. Oncotarget 2017; 7:43432-43441. [PMID: 27223068 PMCID: PMC5190035 DOI: 10.18632/oncotarget.9468] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2015] [Accepted: 03/29/2016] [Indexed: 12/20/2022] Open
Abstract
Gamma-synuclein (SNCG) is secreted from tumor cells and elevated in the urine of bladder cancer (BCa) patients, however, the diagnostic and prognostic values of urine SNCG for BCa remain unknown. Here, we used enzyme immunoassay and western blotting to measure urine SNCG levels. Patients with BCa or other urological diseases and healthy controls were enrolled at four Chinese hospitals from April 2010 to November 2014. Diagnostic performance was evaluated by analyzing the area under receiver operating characteristic curves (AUROCs). The AUROC was 0.903 ± 0.019 (95% confidence interval [CI], 0.867 - 0.940) for the test and 0.929 ± 0.015 (95% CI, 0.901 - 0.958) for the validation cohort. The optimal cutoff value yielded sensitivities of 68.4%, 62.4% and specificities of 97.4%, 97.8% for the test and validation cohort, respectively. Urine SNCG levels were decreased after tumor resection, but were higher in BCa patients with recurrence than those without (P = 0.001). The urine SNCG levels in patients with urological benign diseases were significantly lower than BCa patients (all P < 0.05) but higher than healthy controls (all P < 0.05). Hematuria did not interfere with the SNCG detection by spiking urine specimens with whole blood. Compared with a nuclear-matrix-protein-22 assay in an additional cohort excluding hematuria, SNCG showed a similar sensitivity and higher specificity. In summary, our results demonstrated that urine SNCG can discriminate BCa from urinary diseases, and is a useful prognosticator of postsurgical recurrence.
Collapse
Affiliation(s)
- Caiyun Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China.,Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Bingbing Shi
- Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Chonghua Hao
- Department of Clinical Laboratory, Shanxi Provincial People's Hospital, Taiyuan, China
| | - Qinghai Wang
- Department of Kidney Transplantation, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Qiang Lv
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Nianzeng Xing
- Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Jianzhong Shou
- Department of Urology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
| | - Like Qu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China.,Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Yanning Gao
- Department of Etiology and Carcinogenesis, Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, China
| | - Chao Qin
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Jiyu Zhao
- Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Chengchao Shou
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China.,Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China
| |
Collapse
|
7
|
He JS, Xie N, Yang JB, Guan H, Chen WC, Zou C, Ouyang YW, Mao YS, Luo XY, Pan Y, Fu L. BCSG1 siRNA delivered by lentiviral vector suppressed proliferation and migration of MDA-MB-231 cells. Int J Mol Med 2017; 41:1659-1664. [PMID: 29286089 DOI: 10.3892/ijmm.2017.3355] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Accepted: 12/13/2017] [Indexed: 11/06/2022] Open
Abstract
Breast cancer-specific gene 1 (BCSG1), also referred to as γ-synuclein (SNCG), is highly expressed in human infiltrating breast carcinomas, but not in normal or benign breast tissue. The present study aimed to evaluate the effects of BCSG1 siRNA delivered by lentiviral vector on breast cancer cells and investigate the underlying mechanisms. BCSG1 RNAi lentiviral vector was constructed and transfected into MDA-MB-231 cells. BCSG1 mRNA levels were determined by quantitative polymerase chain reaction analysis. Cell proliferation, migration and apoptosis were evaluated by using the cell counting kit‑8, Transwell assay and flow cytometry, respectively, followed by western blotting to determine the relative levels of AKT, extracellular signal‑regulated kinase (ERK), p-AKT and p-ERK expression. BCSG1 mRNA levels were significantly reduced in MDA-MB‑231 cells following transfection of BCSG1 siRNA delivered by lentiviral vector. Cell migration and proliferation were significantly decreased and the cell cycle was arrested. Western blot analysis indicated that the protein levels of p-AKT and p-ERK were significantly lower in the BCSG1 siRNA-treated groups compared with the control and negative control groups. Therefore, BCSG1 siRNA delivered by lentiviral vector was able to significantly reduce BCSG1 expression, suppress cell migration and proliferation, possibly through the reduction of the protein levels of p-AKT and p-ERK.
Collapse
Affiliation(s)
- Jin-Song He
- Department of Breast Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518035, P.R. China
| | - Ni Xie
- Biobank, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China
| | - Jian-Bo Yang
- Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota, MN Twin Cities, MN 55455, USA
| | - Hong Guan
- Department of Pathology, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China
| | - Wei-Cai Chen
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China
| | - Chang Zou
- Clinical Research Centre, Shenzhen People's Hospital, Shenzhen, Guangdong 518020, P.R. China
| | - Yi-Wen Ouyang
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China
| | - You-Sheng Mao
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China
| | - Xue-Ying Luo
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China
| | - Yue Pan
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China
| | - Li Fu
- Cancer Research Centre, School of Medicine, Shenzhen University, Shenzhen, Guangdong 518060, P.R. China
| |
Collapse
|
8
|
Winder AD, Maniar KP, Wei JJ, Liu D, Scholtens DM, Lurain JR, Schink JC, Buttin BM, Filiaci VL, Lankes HA, Ramirez NC, Park K, Singh M, Lieberman RW, Mannel RS, Powell MA, Backes FJ, Mathews CA, Pearl ML, Secord AA, Peace DJ, Mutch DG, Creasman WT, Kim JJ. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer 2016; 123:1144-1155. [PMID: 27926776 DOI: 10.1002/cncr.30477] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Revised: 10/19/2016] [Accepted: 11/04/2016] [Indexed: 01/13/2023]
Abstract
BACKGROUND Synuclein-γ (SNCG) is highly expressed in advanced solid tumors, including uterine serous carcinoma (USC). The objective of the current study was to determine whether SNCG protein was associated with survival and clinical covariates using the largest existing collection of USCs from the Gynecologic Oncology Group (GOG-8023). METHODS High-density tissue microarrays (TMAs) of tumor tissues from 313 patients with USC were stained by immunohistochemistry for SNCG, p53, p16, FOLR1, pERK, pAKT, ER, PR, and HER2/neu. Associations of SNCG and other tumor markers with overall and progression-free survival were assessed using log-rank tests and Cox proportional-hazards models, which also were adjusted for age, race, and stage. RESULTS The overall survival at 5 years was 46% for women with high SNCG expression and 62% for those with low SNCG expression (log-rank P = .021; hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.91-1.9 in adjusted Cox model). The progression-free survival rate at 5 years was worse for women who had high SNCG expression, at 40%, compared with 56% for those who had low SNCG expression (log-rank P = .0081; HR, 1.36; 95% CI, 0.96-1.92 in adjusted Cox model). High levels of both p53 and p16 were significantly associated with worse overall survival (p53: HR, 4.20 [95% CI, 1.54-11.45]; p16: HR, 1.95 [95% CI, 1.01-3.75]) and progression-free survival (p53: HR, 2.16 [95% CI, 1.09-4.27]; p16: HR, 1.53 [95% CI, 0.87-2.69]) compared with low levels. CONCLUSIONS This largest collection of USCs to date demonstrates that SNCG was associated with poor survival in univariate analyses. SNCG does not predict survival outcome independent of p53 and p16 in models that jointly consider multiple markers. Cancer 2017;123:1144-1155. © 2016 American Cancer Society.
Collapse
Affiliation(s)
- Abigail D Winder
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois
| | - Kruti P Maniar
- Division of Surgical Pathology, Department of Pathology, Northwestern University, Chicago, Illinois
| | - Jian-Jun Wei
- Division of Surgical Pathology, Department of Pathology, Northwestern University, Chicago, Illinois
| | - Dachao Liu
- Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Denise M Scholtens
- Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - John R Lurain
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois
| | - Julian C Schink
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Spectrum Health, Grand Rapids, Michigan
| | - Barbara M Buttin
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois
| | - Virginia L Filiaci
- Statistics and Data Management Center, NRG Oncology, Buffalo, New York.,Roswell Park Cancer Institute, Buffalo, New York
| | - Heather A Lankes
- Statistics and Data Management Center, NRG Oncology, Buffalo, New York.,Roswell Park Cancer Institute, Buffalo, New York
| | - Nilsa C Ramirez
- Biopathology Center and Gynecologic Oncology Group Tissue Bank, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio
| | - Kay Park
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Meenakshi Singh
- Department of Pathology, University of Kansas School of Medicine and Medical Center, Kansas City, Kansas
| | - Richard W Lieberman
- Department of Obstetrics and Gynecology, University of Michigan Health System, Ann Arbor, Michigan.,Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan
| | - Robert S Mannel
- Department of Gynecologic Oncology, The Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Matthew A Powell
- Division of Gynecologic Oncology, Washington University School of Medicine, St Louis, Missouri
| | - Floor J Backes
- Division of Gynecologic Oncology, Ohio State University and James Comprehensive Cancer Center, Columbus, Ohio
| | - Cara A Mathews
- Division of Obstetrics and Gynecology, Women and Infants Hospital, Providence, Rhode Island
| | - Michael L Pearl
- Department of Obstetrics, Gynecology, and Reproductive Medicine, Stony Brook University Medical Center, Stony Brook, New York
| | - Angeles Alvarez Secord
- Department of Obstetrics/Gynecology, Division of Gynecology Oncology, Duke University Medical Center, Durham, North Carolina
| | - David J Peace
- Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, Illinois
| | - David G Mutch
- Division of Gynecologic Oncology, Washington University School of Medicine, St Louis, Missouri
| | - William T Creasman
- Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina
| | - J Julie Kim
- Division of Reproductive Science in Medicine, Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois
| |
Collapse
|
9
|
Strohl A, Mori K, Akers S, Bshara W, Buttin B, Frederick PJ, Helenowski IB, Morrison CD, Odunsi K, Schink JC, Scholtens DM, Wei JJ, Kim JJ. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease. J Ovarian Res 2016; 9:75. [PMID: 27809878 PMCID: PMC5094138 DOI: 10.1186/s13048-016-0281-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Accepted: 10/17/2016] [Indexed: 11/21/2022] Open
Abstract
Background Synuclein gamma (SNCG) expression is associated with advanced disease and chemoresistance in multiple solid tumors. Our goal was to determine if SNCG protein expression in ovarian cancer was correlated with clinicopathologic variables and patient outcomes. Methods Tissue microarrays from primary tumors of 357 ovarian, fallopian tube, and primary peritoneal cancer patients, who underwent primary surgery at Roswell Park Cancer Institute between 1995 and 2007, were immunohistochemically stained for SNCG. A pathologist blinded to patient data scored tumors as positive if ≥10 % of the sample stained for SNCG. Medical records were reviewed for clinicopathologic and demographic variables. Between the positive and negative groups, Wilcoxon rank-sum test was used to compare the median ages and Fisher’s exact test was used to compare groups in categorical variables. Cox proportional hazard models examined associations between SNCG and overall and progression-free survival. Results The median follow-up was 36 months, median overall survival was 39 months, and median progression-free survival was 18 months. SNCG presence was associated with clinical variables of serous histology, grade 3 disease, suboptimal debulking, ascites at surgery, FIGO stage III-IV cancer, or initial CA-125 level >485. There was no significant difference in overall survival (HR 1.06 95 % CI 0.81–1.39 P 0.69) or progression-free survival (HR 1.16 95 % CI 0.89–1.50 P 0.28) for patients with or without SNCG expression. Conclusions SNCG expression in ovarian cancer is frequent in patients with high-risk features, but it does not correlate with chemotherapy response, overall survival, or progression-free survival. Electronic supplementary material The online version of this article (doi:10.1186/s13048-016-0281-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Anna Strohl
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA
| | - Kristina Mori
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA
| | - Stacey Akers
- Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, USA
| | - Wiam Bshara
- Department of Pathology, Roswell Park Cancer Institute, Buffalo, USA
| | - Barbara Buttin
- Gynecologic Oncology Program, Cadence Physician Group, Warrenville, USA
| | - Peter J Frederick
- Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, USA
| | - Irene B Helenowski
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, USA
| | - Carl D Morrison
- Department of Pathology, Roswell Park Cancer Institute, Buffalo, USA
| | - Kunle Odunsi
- Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, USA
| | - Julian C Schink
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA
| | - Denise M Scholtens
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, USA
| | - Jian-Jun Wei
- Department of Pathology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 251 East Huron Street, Feinberg 7-334, Chicago, IL, 60611, USA. .,Division of Reproductive Science in Medicine, Department of Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 303 E. Superior Street, 4-117, Chicago, IL, 60611, USA.
| | - J Julie Kim
- Division of Reproductive Science in Medicine, Department of Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 303 E. Superior Street, 4-117, Chicago, IL, 60611, USA.
| |
Collapse
|
10
|
Liu C, Qu L, Shou C. Role and Characterization of Synuclein-γ Unconventional Protein Secretion in Cancer Cells. Methods Mol Biol 2016; 1459:215-227. [PMID: 27665562 DOI: 10.1007/978-1-4939-3804-9_15] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Synuclein-γ (SNCG), the third member of synuclein family, is implicated in both neurodegenerative diseases and cancer. Overexpression of SNCG in cancer cells is linked to tumor progression and chemoresistance. Without any known signal sequence required for conventional protein secretion, SNCG is elevated in the serum of cancer patients and the medium of cultured cancer cells. SNCG actively secretes from cancer cells and extracellular SNCG promotes malignant phenotypes of cancer cells. Here, we describe methods for the characterization of SNCG as an unconventional secretion protein from cancer cells and investigation of the effect of extracellular SNCG on the phenotypes of cancer cells.
Collapse
Affiliation(s)
- Caiyun Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing, China
- Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Like Qu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing, China
- Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Chengchao Shou
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing, China.
- Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China.
| |
Collapse
|
11
|
Zhuang Q, Liu C, Qu L, Shou C. Synuclein-γ promotes migration of MCF7 breast cancer cells by activating extracellular-signal regulated kinase pathway and breaking cell-cell junctions. Mol Med Rep 2015; 12:3795-3800. [PMID: 25997706 DOI: 10.3892/mmr.2015.3799] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2014] [Accepted: 04/10/2015] [Indexed: 11/06/2022] Open
Abstract
Synuclein-γ (SNCG), a synuclein family member, promotes migration, invasion and metastasis of tumor cells; however, the mechanism remains unclear. The present study investigated the effect of SNCG on malignant phenotypes of MCF7 cells using cell proliferation analysis, cell migration assays and wound healing assays, and verified its effects on extracellular‑signal regulated kinase (Erk) activation and epithelial to mesenchymal transition‑related markers using western blotting. The results indicated that SNCG increased migration (P<0.05) but not proliferation (P=0.711) of MCF7 cells. It was also demonstrated that SNCG activated the Erk pathway and an inhibitor of Erk signaling significantly counteracted SNCG‑induced migration. Furthermore, it was shown that SNCG downregulated levels of tight junctions‑associated factors E‑cadherin and ZO‑1, while inhibiting the Erk pathway did not affect their levels. In conclusion, SNCG may promote MCF7 cell migration through activating the Erk pathway and breaking cell-cell junctions.
Collapse
Affiliation(s)
- Qing Zhuang
- Department of Biochemistry and Molecular Biology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
| | - Caiyun Liu
- Department of Biochemistry and Molecular Biology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
| | - Like Qu
- Department of Biochemistry and Molecular Biology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
| | - Chengchao Shou
- Department of Biochemistry and Molecular Biology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
| |
Collapse
|
12
|
Zhao J, Xing N. Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry. Med Sci Monit 2014; 20:2550-5. [PMID: 25479371 PMCID: PMC4266204 DOI: 10.12659/msm.892927] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Background Previous studies have shown that the expression level of γ-synuclein (SNCG) is associated with progression of many different malignant tumors. In this study, we discuss and assess the prognostic ability of SNCG in bladder cancer. Material/Methods Medical records (2005–2013) were retrospectively reviewed for the population of interest. SNCG expression was identified immunohistochemically from bladder cancer tissues of 113 bladder cancer patients. The survival rate was calculated by the Kaplan-Meier method. Cox proportional hazard regression model was used for analysis of predictors of bladder cancer. Results SNCG was overexpressed in bladder cancer tissues compared with the normal bladder tissues (p<0.0001). SNCG expression in bladder cancer tissue was strongly related to tumor stage. However, SNCG level was not a prognostic factor of survival. Conclusions Our results demonstrate that SNCG is highly expressed in bladder cancer tissue and its expression is stage-specific, but it is not helpful for predicting outcome in bladder cancer patients.
Collapse
Affiliation(s)
- Jiyu Zhao
- Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China (mainland)
| | - Nianzeng Xing
- Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China (mainland)
| |
Collapse
|
13
|
Liu C, Qu L, Lian S, Tian Z, Zhao C, Meng L, Shou C. Unconventional secretion of synuclein-γ promotes tumor cell invasion. FEBS J 2014; 281:5159-71. [PMID: 25229320 DOI: 10.1111/febs.13055] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2014] [Revised: 09/04/2014] [Accepted: 09/15/2014] [Indexed: 12/21/2022]
Abstract
Synuclein-γ (SNCG) is a chaperone protein and exists mainly in the cytoplasm. SNCG confers chemoresistance, and is a potential unfavorable biomarker for multiple types of cancer. Our previous work demonstrated that SNCG could be detected in the serum of cancer patients and the medium of cultured cancer cells, but the mechanism of SNCG secretion and its biological roles are unknown. Here, we showed that SNCG levels in the culture medium were positively correlated with cancer cell densities and the concentrations of fetal bovine serum added. SNCG secretion was unaffected by brefeldin A, an inhibitor of the classic protein transport pathway, but was antagonized by exosome inhibitor, lysosome inhibitor, ABC transporter inhibitor, and phosphatidylinositide 3-kinase inhibitor, and knockdown of Rab27a. Ultracentrifugation fractionation revealed that intracellular SNCG was present as both free and vesicle-associated forms, but that the extracellular SNCG was mainly free. The results of reciprocal coimmunoprecipitation experiments showed an interaction between SNCG and flotillin-2, a marker of exosomes and lipid rafts. Moreover, we demonstrated that SNCG, both secreted from tumor cells and exogenously added, markedly promoted cancer cell migration and invasion, but had no effect on noncancerous cells. These findings suggest that SNCG is actively secreted by cancer cells via an unconventional secretion pathway and contributes to aggressive phenotypes of cancer cells.
Collapse
Affiliation(s)
- Caiyun Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China
| | | | | | | | | | | | | |
Collapse
|
14
|
He J, Xie N, Yang J, Guan H, Chen W, Wu H, Yuan Z, Wang K, Li G, Sun J, Yu L. siRNA-Mediated Suppression of Synuclein γ Inhibits MDA-MB-231 Cell Migration and Proliferation by Downregulating the Phosphorylation of AKT and ERK. J Breast Cancer 2014; 17:200-6. [PMID: 25320617 PMCID: PMC4197349 DOI: 10.4048/jbc.2014.17.3.200] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2014] [Accepted: 09/04/2014] [Indexed: 11/30/2022] Open
Abstract
Purpose Synuclein-γ (SNCG), which was initially identified as breast cancer specific gene 1, is highly expressed in advanced breast cancers, but not in normal or benign breast tissue. This study aimed to evaluate the effects of SNCG siRNA-treatment on breast cancer cells and elucidate the associated mechanisms. Methods Vectors containing SNCG and negative control (NC) siRNAs were transfected into MDA-MB-231 cells; mRNA levels were determined by real-time polymerase chain reaction. Cell proliferation was evaluated using the MTT assay, cell migration was assessed by the Transwell assay, apoptosis and cell cycle analyses were conducted with the flow cytometer, and Western blot analysis was performed to determine the relative levels of AKT, ERK, p-AKT, and p-ERK expression. Results SNCG mRNA levels were significantly reduced in MDA-MB-231 cells transfected with SNCG siRNA. Our results indicate that in SNCG siRNA-treated cells, cell migration and proliferation decreased significantly, apoptosis was induced, and the cell cycle was arrested. Western blot analysis indicated that the protein levels of p-AKT and p-ERK were much lower in the SNCG siRNA-treated groups, than in the control and NC groups. Conclusion SNCG siRNA could decrease the migration and proliferation of breast cancer cells by downregulating the phosphorylation of AKT and ERK.
Collapse
Affiliation(s)
- Jingsong He
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China
| | - Ni Xie
- Biobank, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China
| | - Jianbo Yang
- Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
| | - Hong Guan
- Department of Pathology, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China
| | - Weicai Chen
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China
| | - Huisheng Wu
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China
| | - Zishan Yuan
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China
| | - Kun Wang
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China
| | - Guojin Li
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China
| | - Jie Sun
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China
| | - Limin Yu
- Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China
| |
Collapse
|
15
|
Synuclein γ protects Akt and mTOR and renders tumor resistance to Hsp90 disruption. Oncogene 2014; 34:2398-405. [DOI: 10.1038/onc.2014.126] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2013] [Revised: 02/03/2014] [Accepted: 03/17/2014] [Indexed: 12/30/2022]
|
16
|
Shao Y, Wang B, Shi D, Miao S, Manivel P, Krishna R, Chen Y, Eric Shi Y. Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption. Mol Oncol 2014; 8:1521-31. [PMID: 24998446 DOI: 10.1016/j.molonc.2014.05.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Revised: 04/25/2014] [Accepted: 05/22/2014] [Indexed: 10/25/2022] Open
Abstract
Hsp90 is an important driver of stabilization and activation of several oncogenic proteins in many key pathways in oncogenesis, including HER2. The present study demonstrated that synuclein gamma (SNCG) prevents the protein degradation and protects the function of HER2 in the condition when the function of Hsp90 is blocked. Disruption of Hsp90 resulted in a significant degradation of HER2 and the loss of activity. However, SNCG completely recovered Hsp90 disruption-mediated losses of HER2 and the function. SNCG bound to HER2 in the presence and absence of Hsp90. Specifically, the C-terminal (Gln106-Asp127) of SNCG bound to the loop connecting αC helix and β4 sheet of the kinase domain of HER2. SNCG renders resistance to 17-AAG-induced tumor suppression in tumor xenograft. Crossing SNCG transgenic mice with HER2 mice stimulated HER2-induced tumor growth and rendered resistance to Hsp90 disruption. The present study indicates that SNCG protects Hsp90 client protein of HER2, and renders resistance to Hsp90 disruption.
Collapse
Affiliation(s)
- Yongfeng Shao
- Department of Cardiothoracic Surgery the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Bingchan Wang
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | | | - Suyu Miao
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Panneerselvam Manivel
- Centre for Bioinformatics, School of Life Science, Pondicherry University, Puducherry, India
| | - Ramadas Krishna
- Centre for Bioinformatics, School of Life Science, Pondicherry University, Puducherry, India
| | - Yiding Chen
- Department of Surgery, Women's Hospital, Zhejiang University School of Medicine, China
| | - Y Eric Shi
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
| |
Collapse
|
17
|
Wan F, Dong L, Zhang F, Wang Y, Chen F, Ni S, Chen Y, Long J. Clinical study of the relationship between γ-synuclein and the response of neoadjuvant chemotherapy in breast cancer. J Int Med Res 2013; 41:743-53. [PMID: 23696593 DOI: 10.1177/0300060513484434] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVES To investigate relationships between several protein biomarkers and clinical responses to neoadjuvant chemotherapy (NAC) in breast cancer. METHODS Tumour tissue samples from female patients with locally advanced breast carcinoma (stages IIA to IIIC), treated with NAC regimens (including 5-fluorouracil, epirubicin, cyclophosphamide and docetaxel, epirubicin, cyclophosphamide) were analysed retrospectively. Immunohistochemical analysis was used to test for protein levels of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER)-2, protein 53 (p53) and γ-synuclein. Relationships between protein biomarkers and responses to NAC were analysed by multivariate logistic regression analysis. RESULTS Data from 154 patients (median age, 51 years; range 27-75 years) were included. Multivariate logistic regression analysis showed that γ-synuclein was an independent predictor of NAC objective response rate, and a statistically significant relationship was observed between NAC regimen, γ-synuclein levels and pathological complete response rate. CONCLUSIONS These study findings suggest that γ-synuclein - in combination with other markers such as ER, PR and HER-2 - may serve as a biomarker for response to NAC in breast cancer and warrants further study.
Collapse
Affiliation(s)
- Fan Wan
- Department of Surgery, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
INTRODUCTION Combination of multiple biomarkers representing distinct aspects of tumor biology will have a better prognostic value. This study was to identify prognostic subgroups of colon adenocarcinoma by combined analysis of synuclein-gamma (SNCG), a human homologue of piwi (Hiwi), phosphatase of regenerating liver-3 (PRL-3), arrest-defective protein 1, homolog A (ARD1) and clinicopathologic features in 225 colon adenocarcinoma specimens. METHODS Immunohistochemistry for 4 tumor markers was performed in whole tissue sections from 225 colon adenocarcinoma patients with complete clinicopathologic data and up to 10-year follow-up. The immunohistochemical expression patterns were examined individually and in multimarker combinations. Univariate and multivariate analyses were performed to identify independent predictive markers of poor outcome. RESULTS With the tumor marker positive rate [32.0% (62/225) for SNCG; 76.9% (173/225) for combined SNCG/Hiwi/PRL-3/ARD1] and the detecting accuracy [61.9% (252/407) for SNCG; 82.6% (336/407) for combined SNCG/Hiwi/PRL-3/ARD1] increasing, incremental value of combined SNCG/Hiwi/PRL-3/ARD1 (P < 0.001; hazard ratios (HR), 3.2) to poor outcome was found. Stratified by lymph node, Hiwi alone (P = 0.004; HR, 3.2) led to poor outcome in patients without lymph node metastasis (LN-), and SNCG (P < 0.001; HR, 2.5) had independently poor prognostic value for patients with lymph node metastasis (LN+). CONCLUSIONS Multimarker phenotypes improved tumor positive rate, detecting accuracy and prognostic value. In addition, a subgroup of more aggressive tumors can be identified by evaluating Hiwi level in LN- cancer, and SNCG level in LN+ cancer.
Collapse
|
19
|
Liu C, Dong B, Lu A, Qu L, Xing X, Meng L, Wu J, Eric Shi Y, Shou C. Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen. BMC Cancer 2010; 10:359. [PMID: 20604972 PMCID: PMC2912867 DOI: 10.1186/1471-2407-10-359] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2009] [Accepted: 07/07/2010] [Indexed: 01/21/2023] Open
Abstract
Background Synuclein gamma (SNCG), initially identified as a breast cancer specific gene, is aberrantly expressed in many different malignant tumors but rarely expressed in matched nonneoplastic adjacent tissues. In this study, we investigated the prognostic potential of SNCG in colon cancer particularly in the patients with normal carcinoembryonic antigen (CEA) levels. Methods SNCG levels were assessed immunohistochemically in cancer tissues from 229 colon adenocarcinoma patients with a mean follow-up of 44 months. Correlations between SNCG levels and clinicopathologic features, preoperative serum CEA level, and clinical outcome were analyzed statistically using SPSS. Results SNCG levels in colon adenocarcinoma were closely associated with intravascular embolus and tumor recurrence but independent of preoperative serum CEA levels. SNCG expression was an independent prognostic factor of a shorter disease-free survival (DFS) and overall survival (OS) (P < 0.0001). Multivariate analysis revealed that both tissue SNCG and serum CEA were independent prognostic factors of DFS (P = 0.001, <0.0001, respectively) for 170 patients with colon adenocarcinomas. Importantly, SNCG remained a prognostic determinant of DFS and OS (P = 0.001, 0.002) for 97 patients with normal preoperative serum CEA level. Conclusions Our results suggest for the first time that SNCG is a new independent predicator for poor prognosis in patients with colon adenocarcinoma, including those with normal CEA levels. Combination of CEA with SNCG improves prognostic evaluation for patients with colon adenocarcinoma.
Collapse
Affiliation(s)
- Caiyun Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, 52 Fucheng Road, Haidian District, Beijing 100142, China
| | | | | | | | | | | | | | | | | |
Collapse
|